maralixibat chloride maralixibat chloride maralixibat chloride, sold under the brand name livmarli, is a medication used to treat cholestatic pruritus in people with alagille syndrome. maralixibat chloride is an ileal bile acid transporter (ibat) inhibitor. maralixibat chlorideclinical datatrade nameslivmarliother nameslum001ahfs/drugs.commonographlicense data us dailymed: maralixibat chloride routes ofadministrationby mouthdrug classileal bile acid transporter (ibat) inhibitoratc codea05ax04 (who) legal statuslegal status us: ℞-only eu: rx-only identifiers iupac name 1-phenoxy}methyl)benzyl]-4-aza-1-azoniabicyclooctane cas number716313-53-0as salt: 228113-66-4drugbankdb16226as salt: dbsalt003196chemspider8007375as salt: 8007374uniiuyb6uof69las salt: v78m04f0xckeggd10951as salt: d10952chemblchembl363392as salt: chembl17879chemical and physical dataformulac40h56cln3o4smolar mass710.42 g·mol−13d model (jsmol)interactive image smiles ccccc1(cccc)cs(=o)(=o)c2=cc=c(c=c2(1o)c1=cc=c(occ2=cc=c(c34ccn(cc3)cc4)c=c2)c=c1)n(c)c inchi inchi=1s/c40h56n3o4s/c1-5-7-19-40(20-8-6-2)30-48(45,46)37-18-15-34(41(3)4)27-36(37)38(39(40)44)33-13-16-35(17-14-33)47-29-32-11-9-31(10-12-32)28-43-24-21-42(22-25-43)23-26-43/h9-18,27,38-39,44h,5-8,19-26,28-30h2,1-4h3/q+1/t38-,39-/m1/s1key:stpkwkpurvsajf-ljewaxopsa-n the most common side effects include diarrhea and abdominal pain (belly ache). maralixibat chloride was approved for medical use in the united states in september 2021, and in the european union in december 2022. medical uses maralixibat chloride is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome. history the u.s. food and drug administration (fda) granted the application for maralixibat chloride orphan drug designations in 2013, and in 2020. society and culture legal status on 13 october 2022, the committee for medicinal products for human use (chmp) of the european medicines agency (ema) adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product livmarli, intended for the treatment of cholestatic pruritus in patients with alagille syndrome (algs). the applicant for this medicinal product is mirum pharmaceuticals international b.v. maralixibat chloride was approved for medical use in the european union in december 2022. names maralixibat chloride is the international nonproprietary name (inn).